Difficulty: Medium
Average Score: 68%
Practice
A healthcare provider is caring for a client who is prescribed Digoxin. Which of the following laboratory values should the provider monitor to assess for potential toxicity?
Correct answer
B
Rationale
In the context of pharmacology, it is crucial for healthcare providers to understand the specific monitoring requirements for medications to ensure patient safety and effective treatment. In the case of Digoxin, which is commonly prescribed for heart conditions, monitoring potassium levels is essential to assess for potential toxicity. Digoxin works by increasing intracellular calcium levels, and hypokalemia can potentiate its toxicity, leading to serious cardiac complications such as arrhythmias.
Monitoring sodium levels (option A) is not directly related to Digoxin toxicity. While sodium imbalances can impact heart function, it is not the primary concern when monitoring for Digoxin toxicity.
Similarly, monitoring magnesium levels (option C) is important for some medications but is not a primary concern for Digoxin toxicity. Magnesium imbalances can also affect cardiac function, but they are not the main focus when assessing Digoxin toxicity.
Monitoring calcium levels (option D) is not typically required when assessing Digoxin toxicity. Calcium levels can influence cardiac contractility, but they are not directly linked to Digoxin toxicity as potassium levels are.
Educationally, understanding the rationale behind monitoring potassium levels in Digoxin therapy highlights the interconnectedness of electrolytes and medications in pharmacology. It emphasizes the importance of comprehensive patient assessment and monitoring to prevent adverse drug reactions and ensure optimal therapeutic outcomes.
Monitoring sodium levels (option A) is not directly related to Digoxin toxicity. While sodium imbalances can impact heart function, it is not the primary concern when monitoring for Digoxin toxicity.
Similarly, monitoring magnesium levels (option C) is important for some medications but is not a primary concern for Digoxin toxicity. Magnesium imbalances can also affect cardiac function, but they are not the main focus when assessing Digoxin toxicity.
Monitoring calcium levels (option D) is not typically required when assessing Digoxin toxicity. Calcium levels can influence cardiac contractility, but they are not directly linked to Digoxin toxicity as potassium levels are.
Educationally, understanding the rationale behind monitoring potassium levels in Digoxin therapy highlights the interconnectedness of electrolytes and medications in pharmacology. It emphasizes the importance of comprehensive patient assessment and monitoring to prevent adverse drug reactions and ensure optimal therapeutic outcomes.